BlackRock Investment Management’s Theriva Biologics TOVX Stock Holding History

BlackRock Investment Management’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$223K	Buy	33 +1	+3%	+$10.3K	﹤0.01%	3220
2016 Q3	$484K	Hold	32	–	–	﹤0.01%	3064
2016 Q2	$508K	Buy	32 +31	+3,100%	+$584K	﹤0.01%	3064
2016 Q1	$25K	Hold	1	–	–	﹤0.01%	3337
2015 Q4	$25K	Hold	1	–	–	﹤0.01%	3374
2015 Q3	$25K	Hold	1	–	–	﹤0.01%	3378
2015 Q2	$25K	Hold	1	–	–	﹤0.01%	3380
2015 Q1	$21K	Hold	1	–	–	﹤0.01%	3436
2014 Q4	$14K	Hold	1	–	–	﹤0.01%	3557
2014 Q3	$14K	Hold	1	–	–	﹤0.01%	3536
2014 Q2	$13K	Buy	+1	New	+$15.9K	﹤0.01%	3542

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

BlackRock Investment Management's TOVX Position: Q4 2016 in Review

BlackRock Investment Management increased its Theriva Biologics (TOVX) stake by 3.1% in Q4 2016, buying an estimated $10.3K and bringing the position to 33 shares worth $223K. The position accounts for ﹤0.01% of the portfolio, ranked #3220.

BlackRock Investment Management first reported a position in TOVX in Q2 2014 and has held it in 11 quarters since. The position peaked at $508K in Q2 2016. 70 funds tracked by Wall St. Rank hold TOVX as of Q4 2016.

BlackRock Investment Management held 33 shares of Theriva Biologics worth $223K as of Q4 2016.
BlackRock Investment Management bought 1 Theriva Biologics share in Q4 2016, an estimated $10.3K.
Theriva Biologics made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3220 holding.
BlackRock Investment Management first reported a position in Theriva Biologics in Q2 2014 and has held it in 11 quarters since.
BlackRock Investment Management's Theriva Biologics position peaked at $508K in Q2 2016.
70 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.